The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price will be on watch on Wednesday following the release of its half year results.
How did Fisher & Paykel Healthcare perform in the first half?
Like rival ResMed Inc. (ASX: RMD), Fisher & Paykel Healthcare has been a strong performer in the first half of FY 2020.
During the six months to September 30, it delivered operating revenue of NZ$570.9 million and a net profit after tax of NZ$121.2 million. This was an increase of 12% and 24% increase, respectively, on the prior corresponding period.
The company’s managing director and CEO, Lewis Gradon, explained that the Hospital product group was the main driver of growth during the half.
He said: “We’ve had a strong start to the 2020 financial year, mainly driven by our Hospital product group, which delivered operating revenue growth of 19 per cent. We saw strong demand across our Hospital product portfolio, but in particular, for our Optiflow and Airvo systems, which continued to benefit from the growing body of clinical research in the use of nasal high flow therapy.”
Over the period the Hospital product group reported a 19% increase in operating revenue to a record NZ$353.6 million. This accounts for 62% of its total operating revenue.
This was supported by modest growth from its Homecare product group. This product group includes products used in the treatment of obstructive sleep apnea (OSA) and respiratory support in the home. Homecare operating revenue rose 2% to NZ$214.7 million during the half.
Mr Gradon advised: “Revenue from our new F&P Vitera full face mask in Australasia, Canada and Europe has partially offset declines in sales of some of our legacy OSA masks, resulting in Homecare revenue in line with expectations for the first half. Vitera was launched in the United States in October, and we are encouraged by the early response from customers.”
This strong half allowed company’s board to declare an interim dividend of 12 NZ cents per share, which is an increase of 23% on the last year’s interim dividend.
The company’s chief executive appears confident on the second half.
He said: “In the second half of the 2020 financial year we anticipate consistent underlying trends in our Hospital product group. Assuming a moderate flu season for FY20, for the second half we expect constant currency Hospital revenue growth similar to the second half of FY19.”
“In our Homecare product group we also expect a continuation of recent trends with strong growth in home respiratory support and ongoing pressure in legacy OSA masks, resulting in Homecare revenue for the 2020 financial year similar to the previous financial year, in constant currency terms,” he added.
As a result, the company expects full year operating revenue to be approximately $1.19 billion and net profit after tax to be in the range of approximately NZ$255 million to NZ$265 million. This is in line with its recently upgraded guidance.
The post Fisher & Paykel Healthcare delivers strong half year profit growth appeared first on Motley Fool Australia.
Not sure about Fisher & Paykel Healthcare? Then check out these highly rated growth shares.
Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares for 2019
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- 5 Stocks for Potentially Building Wealth After 50
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019